Literature DB >> 29134489

The quick loss of carbapenem susceptibility in Pseudomonas aeruginosa at intensive care units.

Yamin Zou1,2, Jiangping Lian3, Ying Di4, Haisheng You1, Hongping Yao1, Junhui Liu5, Yalin Dong6.   

Abstract

Background Patients colonized with carbapenem-susceptible Pseudomonas aeruginosa (CSPA) strains upon admission to the intensive care unit (ICU) tend to be quickly followed by detected carbapenem-resistant P. aeruginosa strains after admission. Objective To assess the risk factors associated with the quick loss of carbapenem susceptibility and to identify time threshold of prior antimicrobial exposure for the loss during ICU stay. Setting A tertiary-care teaching hospital with 2560 beds located in the northwest region of China. Method A retrospective observational study was conducted between January 2013 and April 2016 at ICUs. Logistic regression analysis was used to assess risk factors, and receiver operating characteristic (ROC) analyses were constructed to identify the time threshold. Main outcome measure The time threshold and risk factors for the quick loss of carbapenem susceptibility. Results Among the 84 patients with CSPA initially, 32 (38.1%) patients were observed to have a loss of carbapenem susceptibility during ICU stay. Logistic regression analyses showed that previous carbapenem exposure was only independently associated with the loss of carbapenem susceptibility (odds ratio 13.16; 95% CI 3.13-55.24; p < 0.001). The optimal cut-off was 3.5 days on ROC curve, indicating the high risk for loss of susceptibility. Conclusion In order to alleviate selective pressure caused by antipseudomonal carbapenems exposure, continued research is needed to determine the most appropriate carbapenems treatment strategies.

Entities:  

Keywords:  Antibiotics resistance; Carbapenem; China; Intensive care; Time threshold; Treatment strategy

Mesh:

Substances:

Year:  2017        PMID: 29134489     DOI: 10.1007/s11096-017-0524-5

Source DB:  PubMed          Journal:  Int J Clin Pharm


  29 in total

1.  In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.

Authors:  Mickaël Riou; Sylviane Carbonnelle; Laëtitia Avrain; Narcisa Mesaros; Jean-Paul Pirnay; Florence Bilocq; Daniel De Vos; Anne Simon; Denis Piérard; Frédérique Jacobs; Anne Dediste; Paul M Tulkens; Françoise Van Bambeke; Youri Glupczynski
Journal:  Int J Antimicrob Agents       Date:  2010-12       Impact factor: 5.283

2.  Risk factors for recovery of imipenem- or ceftazidime-resistant pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil.

Authors:  Carlos Magno C B Fortaleza; Maristela P Freire; Djalma de C Moreira Filho; Marcelo de Carvalho Ramos
Journal:  Infect Control Hosp Epidemiol       Date:  2006-08-21       Impact factor: 3.254

Review 3.  Combination therapy for Gram-negative bacteria: what is the evidence?

Authors:  Joumana G Kmeid; Mona M Youssef; Zeina A Kanafani; Souha S Kanj
Journal:  Expert Rev Anti Infect Ther       Date:  2013-10-30       Impact factor: 5.091

4.  Antibiotic exposure and resistance development in Pseudomonas aeruginosa and Enterobacter species in intensive care units.

Authors:  David S Y Ong; Irene P Jongerden; Anton G Buiting; Maurine A Leverstein-van Hall; Ben Speelberg; Jozef Kesecioglu; Marc J M Bonten
Journal:  Crit Care Med       Date:  2011-11       Impact factor: 7.598

5.  Risk factors for development of intestinal colonization with imipenem-resistant Pseudomonas aeruginosa in the intensive care unit setting.

Authors:  Anthony D Harris; J Kristie Johnson; Kerri A Thom; Daniel J Morgan; Jessina C McGregor; Adebola O Ajao; Anita C Moore; Angela C Comer; Jon P Furuno
Journal:  Infect Control Hosp Epidemiol       Date:  2011-07       Impact factor: 3.254

6.  Antimicrobial susceptibility of 2906 Pseudomonasaeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008-2015.

Authors:  Andrew Walkty; Philippe Lagace-Wiens; Heather Adam; Melanie Baxter; James Karlowsky; Michael R Mulvey; Melissa McCracken; George G Zhanel
Journal:  Diagn Microbiol Infect Dis       Date:  2016-10-07       Impact factor: 2.803

7.  Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients.

Authors:  Anthony D Harris; David Smith; Judith A Johnson; Douglas D Bradham; Mary-Claire Roghmann
Journal:  Clin Infect Dis       Date:  2001-12-26       Impact factor: 9.079

8.  Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa.

Authors:  Ellie J C Goldstein; Diane M Citron; Victoria Peraino; Tanya Elgourt; Anne R Meibohm; Shuang Lu
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

9.  Antibiotics involved in the occurrence of antibiotic-resistant bacteria: a nationwide multilevel study suggests differences within antibiotic classes.

Authors:  Houssein Gbaguidi-Haore; Catherine Dumartin; François L'Hériteau; Muriel Péfau; Didier Hocquet; Anne-Marie Rogues; Xavier Bertrand
Journal:  J Antimicrob Chemother       Date:  2012-10-17       Impact factor: 5.790

Review 10.  Epidemiology and Characteristics of Metallo-β-Lactamase-Producing Pseudomonas aeruginosa.

Authors:  Duck Jin Hong; Il Kwon Bae; In-Ho Jang; Seok Hoon Jeong; Hyun-Kyung Kang; Kyungwon Lee
Journal:  Infect Chemother       Date:  2015-06-30
View more
  1 in total

1.  Carbapenem Resistant Pseudomonas aeruginosa Infections in Elderly Patients: Antimicrobial Resistance Profiles, Risk Factors and Impact on Clinical Outcomes.

Authors:  Jie Qin; Chengyun Zou; Jianmin Tao; Tian Wei; Li Yan; Yufei Zhang; Haiying Wang
Journal:  Infect Drug Resist       Date:  2022-04-29       Impact factor: 4.177

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.